 |
0 Diseases |  |
7 Trials |
|
7 Trials |  |
11 News |  |
- || Irene (pyrotinib) / Jiangsu Hengrui Pharma, Cipterbin (inetetamab) / 3SBio
P1 data, Journal, Metastases: Phase 1b trial of anti-HER2 antibody inetetamab and pan-HER inhibitor pyrotinib in HER2-positive advanced lung cancer. (Pubmed Central) - Apr 30, 2024
P1/2
Responses were shown in patients with distinct HER2 aberrations. In summary, inetetamab in combination with pyrotinib demonstrated acceptable safety and antitumor activity among patients with advanced HER2-mutant NSCLC.
- | Cipterbin (inetetamab) / 3SBio
New trial, Real-world evidence, Real-world, Metastases: Real-world Study of Inetetamab in HER2-positive Metastatic Breast Cancer (clinicaltrials.gov) - Mar 12, 2024
P=N/A, N=500, Completed, Sponsor: Liaoning Tumor Hospital & Institute
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma, Cipterbin (inetetamab) / 3SBio
New trial, Metastases: neoPICD: A Prospective, Open, Multicenter Single-arm Clinical Studie of Docetaxel, Carboplatin Combined With Inetetamab and Pyrotinib in the Treatment of Local-advanced HER2-positive Breast Cancer (clinicaltrials.gov) - Feb 15, 2024
P=N/A, N=154, Recruiting, Sponsor: Wang Ouchen
- || Irene (pyrotinib) / Jiangsu Hengrui Pharma, Cipterbin (inetetamab) / 3SBio, Navelbine oral (vinorelbine tartrate oral) / Pierre Fabre
P2 data, Journal, Metastases: Inetetamab combined with pyrotinib and oral vinorelbine for patients with human epidermal growth factor receptor 2 positive advanced breast cancer: A single-arm phase 2 clinical trial. (Pubmed Central) - Feb 8, 2024
P2
The combination regimen of inetetamab, pyrotinib, and oral vinorelbine showed encouraging efficacy and favorable safety in patients with HER2-positive advanced breast cancer and could be considered as an alternative treatment option for the patients. No.NCT05823623; https://www.clinicaltrials.gov/.
- || Cipterbin (inetetamab) / 3SBio
Clinical data, Journal, Metastases: Exploring the clinical outcomes and safety profile of inetetamab treatment in metastatic breast cancer patients: A multicenter assessment of a Chinese-origin recombinant Anti-HER2 monoclonal antibody. (Pubmed Central) - Dec 5, 2023
No.NCT05823623; https://www.clinicaltrials.gov/. Inetetamab demonstrates effectiveness with a manageable safety profile, offering a promising therapeutic option for HER2-positive breast cancer patients who have shown resistance to prior anti-HER2 treatments.
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma, Cipterbin (inetetamab) / 3SBio
New trial, Metastases: Efficacy and safety of Inetetamab plus pyrotiniband and capecitabine in HER2-positive metastatic breast cancer patients with or without brain metastasis (EUDRACT) - Dec 5, 2023
P=N/A, N=40, Recruiting, Sponsor: Xi'an International Medical Center Hospital; Xi'an International Medical Center Hospital
Inetetamab demonstrates effectiveness with a manageable safety profile, offering a promising therapeutic option for HER2-positive breast cancer patients who have shown resistance to prior anti-HER2 treatments. .
- Cipterbin (inetetamab) / 3SBio, Herceptin (trastuzumab) / Roche
Inetetamab combined with sirolimus and chemotherapy in HER2 positive metastatic breast cancer patients with abnormal activation of Pi3k/Akt/mTOR pathway after trastuzumab treatment (Hall 2-3) - Nov 4, 2023 - Abstract #SABCS2023SABCS_1718;
For the metastatic HER2 positive breast cancer patients with abnormal activation of PAM pathway treated with trastuzumab previously, the combination of inetetamab with sirolimus and chemotherapy regimen are equivalent to the combination of pyrotinib and chemotherapy regimen. It demonstrated that combination of inetetamab with sirolimus and chemotherapy could be one of the treatment options for the metastatic HER2 positive breast cancer patients.
- Irene (pyrotinib) / Jiangsu Hengrui Pharma, Cipterbin (inetetamab) / 3SBio
A Multicenter, Retrospective, Real World Study of Inetetamab Combined with Pyrotinib and Vinorelbine as Treatment for HER2-positive Metastatic Breast Cancer (Hall 2-3) - Nov 4, 2023 - Abstract #SABCS2023SABCS_1408;
No treatment-related serious adverse events or treatment-related deaths occurred. Conclusion The combination regimen of inetetamab combined with pyrotinib and vinorelbine showed an encouraging efficacy and favorable safety in patients with HER2 positive metastatic breast cancer.
- Cipterbin (inetetamab) / 3SBio, Perjeta (pertuzumab) / Roche
Updated Results of a Phase II Study: Neoadjuvant Inetetamab Combined with Pertuzumab, Paclitaxel and Carboplatin for Locally Advanced HER2-Positive Breast Cancer (Hall 2-3) - Nov 4, 2023 - Abstract #SABCS2023SABCS_946;
P2
Neoadjuvant therapy with TCbIP demonstrated promising efficacy and manageable toxicity in patients with HER2-positive locally advanced breast cancer. Registration number: NCT05749016 (www.clinicaltrials.gov).
- Irene (pyrotinib) / Jiangsu Hengrui Pharma, Cipterbin (inetetamab) / 3SBio
Effectiveness and safety of inetetamab + pyrotinib + vinorelbine in ?second-line treatment of HER2-positive metastatic breast cancer (Hall 2-3) - Nov 4, 2023 - Abstract #SABCS2023SABCS_466;
Inetetamab + pyrotinib + vinorelbine demonstrates good efficacy and controllable toxicity as a second-line treatment for HER2-positive MBC. This therapeutic regimen provides a viable alternative option for patients who are unable to receive ADCs as the second-line treatment.
- Irene (pyrotinib) / Jiangsu Hengrui Pharma, Cipterbin (inetetamab) / 3SBio, Navelbine oral (vinorelbine tartrate oral) / Pierre Fabre
Inetetamab combined with pyrotinib and oral vinorelbine for patients with HER2-positive metastatic breast cancer: a single-arm phase 2 trial (Hall 2-3) - Nov 4, 2023 - Abstract #SABCS2023SABCS_465;
P2
In this prospective, single-arm, phase 2 trial, patients with HER2-positive metastatic breast cancer after progression on trastuzumab were recruited. The combination regimen of inetetamab plus pyrotinib plus oral vinorelbine showed an encouraging efficacy and favorable safety in patients with HER2 positive metastatic breast cancer.
- Irene (pyrotinib) / Jiangsu Hengrui Pharma, Cipterbin (inetetamab) / 3SBio
A multicenter, retrospective, real-world study of inetetamab combined with pyrotinib and vinorelbine as treatment for HER2-positive metastatic breast cancer (Exhibition area) - Oct 6, 2023 - Abstract #ESMOAsia2023ESMO_Asia_651;
No treatment-related serious adverse events or treatment-related deaths occurred. Conclusions The combination regimen of inetetamab combined with pyrotinib and vinorelbine showed an encouraging efficacy and favorable safety in patients with HER2 -positive metastatic breast cancer.
- | Cipterbin (inetetamab) / 3SBio, utidelone IV (UTD1) / Beijing Biostar Technologies
Enrollment closed, Trial completion date, Metastases: Exploratory Study of Advanced Breast Cancer in HER2 Positive Patients With Failure of Multi-line Therapy Treated by Combination of Inetetamab (Cipterbin) + PD-1 Inhibitor Combined With Utidelone. (clinicaltrials.gov) - Sep 25, 2023
P2, N=46, Active, not recruiting, Sponsor: Henan Cancer Hospital
Conclusions The combination regimen of inetetamab combined with pyrotinib and vinorelbine showed an encouraging efficacy and favorable safety in patients with HER2 -positive metastatic breast cancer. Recruiting --> Active, not recruiting | Trial completion date: Oct 2022 --> Dec 2024
- | Cipterbin (inetetamab) / 3SBio
Journal: Inetetamab, a novel anti-HER2 monoclonal antibody, exhibits potent synergistic anticancer effects with cisplatin by inducing pyroptosis in lung adenocarcinoma. (Pubmed Central) - Sep 18, 2023
In addition, cisplatin enhanced the PBMC-killing ability of inetetamab by inducing GSDMB-mediated pyroptosis, which can be explained by increased secretion of IFN-?. Our study reveals that the anti-HER2 monoclonal antibody inetetamab may be an attractive candidate for LUAD therapy, which opens new avenues for therapeutic interventions for LUAD.
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma, Cipterbin (inetetamab) / 3SBio, Navelbine oral (vinorelbine tartrate oral) / Pierre Fabre
Trial initiation date, Metastases: Inetetamab Combined With Pyrotinib Plus Oral Vinorelbine for the Treatment of HER2-positive Metastatic Breast Cancer (clinicaltrials.gov) - Sep 14, 2023
P2, N=30, Recruiting, Sponsor: The First Affiliated Hospital with Nanjing Medical University
Our study reveals that the anti-HER2 monoclonal antibody inetetamab may be an attractive candidate for LUAD therapy, which opens new avenues for therapeutic interventions for LUAD. Initiation date: Sep 2022 --> Feb 2022
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma, Cipterbin (inetetamab) / 3SBio
New trial, Metastases: Efficacy and Safety of Inetetamab Plus Pyrotiniband and Capecitabine in HER2-positive Metastatic Breast Cancer Patients With or Without Brain Metastasis (clinicaltrials.gov) - Aug 29, 2023
P=N/A, N=40, Active, not recruiting, Sponsor: Yan Xue
- | Cipterbin (inetetamab) / 3SBio
New trial, Real-world evidence, Real-world, Metastases: A Real-world Study of Inetetamab for First-line Treatment of MBC (clinicaltrials.gov) - Aug 7, 2023
P=N/A, N=150, Not yet recruiting, Sponsor: Hunan Cancer Hospital
- Irene (pyrotinib) / Jiangsu Hengrui Pharma, Cipterbin (inetetamab) / 3SBio, utidelone IV (UTD1) / Beijing Biostar Technologies
Preliminary results from a prospective study of inetetamab in combination with pyrotinib and utidelone for HER2-positive metastatic breast cancer (IPUtrial) () - Jul 27, 2023 - Abstract #ESMO2023ESMO_2043;
Conclusions Inetetamab plus pyrotinib and utidelone may be an excellent scheme for HER2-positive metastatic breast cancer. This trial is still ongoing and needs long-term follow-up.
- Irene (pyrotinib) / Jiangsu Hengrui Pharma, Cipterbin (inetetamab) / 3SBio
Effectiveness and safety of vinorelbine + inetetamab + pyrotinib in ?second-line treatment of HER2-positive metastatic breast cancer () - Jul 27, 2023 - Abstract #ESMO2023ESMO_2040;
Conclusions The VIP regimen demonstrated good efficacy and controllable toxicity as a second-line treatment for HER2-positive MBC. This therapeutic regimen provides a viable alternative option for patients who are unable to receive ADCs as the second-line treatment.
- Cipterbin (inetetamab) / 3SBio, Perjeta (pertuzumab) / Roche
Neoadjuvant inetetamab combined with pertuzumab, paclitaxel and carboplatin for locally advanced HER2-positive breast cancer: Primary analysis of a phase II study () - Jul 27, 2023 - Abstract #ESMO2023ESMO_1980;
P2
No significant reduction in the left ventricular ejection fraction was observed in any patient. Conclusions Neoadjuvant therapy with TCbIP has shown promising efficacy and manageable toxicity in patients with HER2-positive LA breast cancer.
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma, Cipterbin (inetetamab) / 3SBio
Retrospective data, Journal, Real-world evidence, Real-world, Metastases: Efficacy and safety of inetetamab-containing regimens in patients with HER2-positive metastatic breast cancer: a real-world retrospective study in China. (Pubmed Central) - Jul 5, 2023
HER2+ MBC patients pretreated with multiple-line therapies still respond to inetetamab-based treatment. Inetetamab combined with vinorelbine and pyrotinib may be the most effective treatment regimen, with a controllable and tolerable safety profile.
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma, Cipterbin (inetetamab) / 3SBio
New trial, Metastases: HER2-VIP: Efficacy and Safety of Inetetamab Combined With Pyrotinib and Vinorelbine in ABC (clinicaltrials.gov) - May 12, 2023
P=N/A, N=100, Recruiting, Sponsor: Zhejiang Cancer Hospital
- Cipterbin (inetetamab) / 3SBio, Perjeta (pertuzumab) / Roche
Neoadjuvant inetetamab combined with pertuzumab, paclitaxel, and carboplatin (TCbIP) for locally advanced HER2-positive breast cancer: Primary analysis of a phase II study. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_4206;
P2
TCbIP displays a promising efficacy (pCR rate of 66.7%) and manageable toxicity in patients with HER2-positive LA breast cancer in the neoadjuvant setting. Clinical trial information: NCT05749016.
- Irene (pyrotinib) / Jiangsu Hengrui Pharma, Cipterbin (inetetamab) / 3SBio
Safety and efficacy of inetetamab in combination with pyrotinib in HER2 mutant patients with non-small cell lung cancer (NSCLC): An open-label, phase Ib trial. (On Demand | Hall A; Poster Bd # 93) - Apr 26, 2023 - Abstract #ASCO2023ASCO_3514;
P1/2
Clinical trial information: NCT05016544. >
- Cipterbin (inetetamab) / 3SBio, AiRuiKa (camrelizumab) / Jiangsu Hengrui Pharma, utidelone (UTD1) / Beijing Biostar Technologies
Anti-HER2 antibody inetetamab plus camrelizumab and utidelone for pretreated HER2-positive metastatic breast cancer: Final results from the phase 2 ICU trial. (On Demand | Hall A; Poster Bd # 263) - Apr 26, 2023 - Abstract #ASCO2023ASCO_3234;
P2
The ICU study showed a favorable benefit-risk profile and is an important option for Chinese patients with HER2-positive MBC after at least two lines of HER2-directed therapies with trastuzumab and TKIs. Clinical trial information: NCT04681287.
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma, Cipterbin (inetetamab) / 3SBio, Navelbine oral (vinorelbine tartrate oral) / Pierre Fabre
New P2 trial, Metastases: Inetetamab Combined With Pyrotinib Plus Oral Vinorelbine for the Treatment of HER2-positive Metastatic Breast Cancer (clinicaltrials.gov) - Apr 21, 2023
P2, N=30, Recruiting, Sponsor: The First Affiliated Hospital with Nanjing Medical University
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma, Cipterbin (inetetamab) / 3SBio, Herceptin (trastuzumab) / Roche
Trial completion date, Trial primary completion date, Real-world evidence, Real-world, Metastases: Inetetamab Combined With Pyrotinib and Vinorelbine as First-line to Third-line Treatment for HER2-positive Metastatic Breast Cancer (clinicaltrials.gov) - Mar 31, 2023
P=N/A, N=100, Recruiting, Sponsor: The First Affiliated Hospital with Nanjing Medical University
Clinical trial information: NCT04681287. Trial completion date: Mar 2023 --> Mar 2024 | Trial primary completion date: Mar 2023 --> Mar 2024
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma, Cipterbin (inetetamab) / 3SBio, Herceptin (trastuzumab) / Roche
New trial, Real-world evidence, Real-world, Metastases: Inetetamab Combined With Pyrotinib and Vinorelbine as First-line to Third-line Treatment for HER2-positive Metastatic Breast Cancer (clinicaltrials.gov) - Mar 13, 2023
P=N/A, N=100, Recruiting, Sponsor: The First Affiliated Hospital with Nanjing Medical University
- | Cipterbin (inetetamab) / 3SBio, Perjeta (pertuzumab) / Roche
New P2 trial, Metastases: Neoadjuvant Inetetamab Combined With Pertuzumab and Paclitaxel/Carboplatin for Breast Cancer (clinicaltrials.gov) - Mar 1, 2023
P2, N=30, Recruiting, Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- | Cipterbin (inetetamab) / 3SBio
Journal, Combination therapy: Systemic investigation of inetetamab in combination with small molecules to treat HER2-overexpressing breast and gastric cancers. (Pubmed Central) - Jan 26, 2023
We showed that pan-TKIs-induced synergistic antitumor effects with inetetamab in the treatment of these two types of cancers and that adding chemotherapeutic agents to the existing TKI plus anti-HER2 monoclonal antibody combination strategies induced additional inhibitory effects, suggesting that such combination strategies may be choices for the treatment of these two tumors. Thus, combination therapies targeting distinct and broad pathways that are essential for tumor growth and survival can be effective for treating metastatic breast cancers and gastric cancers.
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma, Cipterbin (inetetamab) / 3SBio
New P2 trial, Metastases: A Study to Evaluate Inetetamab + Pyrotinib + Chemotherapy in Previously Untreated HER2-Positive Metastatic Breast Cancer (clinicaltrials.gov) - Nov 18, 2022
P2, N=63, Not yet recruiting, Sponsor: Fujian Medical University
- Irene (pyrotinib) / Jiangsu Hengrui Pharma, Cipterbin (inetetamab) / 3SBio
Inetetamab combined with pyrotinib and Chemotherapy in Pretreated Patients with HER2-positive metastatic breast cancer，a single arm，multicenter phase II clinical trial (Hall 1) - Oct 28, 2022 - Abstract #SABCS2022SABCS_1975;
Background: The HER2-targeted drugs selection after trastuzumab failure has become a challenging issue for HER2-positive metastatic breast cancer (MBC) patients. Inetetamab combined with pyrotinib and chemotherapy showed a promising efficacy and a good tolerance in patients with HER2-positive metastatic breast cancer, confirming the synergistic effect between the ADCC optimized monoclonal antibodies and TKIs, which brings more treatment options for HER2- positive metastatic breast cancer.
- | Cipterbin (inetetamab) / 3SBio, utidelone IV (UTD1) / Beijing Biostar Technologies
Trial primary completion date, Metastases: Exploratory Study of Advanced Breast Cancer in HER2 Positive Patients With Failure of Multi-line Therapy Treated by Combination of Inetetamab (Cipterbin) + PD-1 Inhibitor Combined With Utidelone. (clinicaltrials.gov) - Aug 3, 2022
P2, N=46, Recruiting, Sponsor: Henan Cancer Hospital
Inetetamab combined with pyrotinib and chemotherapy showed a promising efficacy and a good tolerance in patients with HER2-positive metastatic breast cancer, confirming the synergistic effect between the ADCC optimized monoclonal antibodies and TKIs, which brings more treatment options for HER2- positive metastatic breast cancer. Trial primary completion date: Apr 2022 --> Nov 2021
- ||| AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma, Irene (pyrotinib) / Jiangsu Hengrui Pharma, Herceptin (trastuzumab) / Roche
Enrollment open, Metastases: Treatment of Dalpiciclib Combined With Pyrotinib for Trastuzumab-sensitive HER2+ Advanced Breast Cancer(DAP-Her-02) (clinicaltrials.gov) - Jun 2, 2022
P2, N=120, Recruiting, Sponsor: Henan Cancer Hospital
Trial primary completion date: Apr 2022 --> Nov 2021 Not yet recruiting --> Recruiting
- Cipterbin (inetetamab) / 3SBio, AiRuiKa (camrelizumab) / Jiangsu Hengrui Pharma, utidelone (UTD1) / Beijing Biostar Technologies
Anti-HER2 antibody inetetamab plus camrelizumab and utidelone for pretreated HER2-positive advanced breast cancer: A single-arm, multicenter, phase 2 study. () - Apr 28, 2022 - Abstract #ASCO2022ASCO_1272;
P2
Previous HER2-targeted therapies included trastuzumab (20 [100%]), pyrotinib (17 [85%]), lapatinib (7 [35%]), pertuzumab (3 [15%]), and margetuximab (2 [10%]). Inetetamab plus camrelizumab and utidelone showed promising efficacy and acceptable safety profile in patients with HER2-positive advanced breast cancer after progression on at least two lines of HER2-directed therapies with trastuzumab and TKIs.
- |||| AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma, Irene (pyrotinib) / Jiangsu Hengrui Pharma, Herceptin (trastuzumab) / Roche
New P2 trial, Metastases: Treatment of Dalpiciclib Combined With Pyrotinib for Trastuzumab-sensitive HER2+ Advanced Breast Cancer(DAP-Her-02) (clinicaltrials.gov) - Apr 13, 2022
P2, N=120, Not yet recruiting, Sponsor: Henan Cancer Hospital
- | Cipterbin (inetetamab) / 3SBio
New P4 trial, Metastases: Inetetamab Combined With Anti-PD-1 Monoclonal Antibody and Albumin-Bound Paclitaxel for HER2+ Metastatic Breast Cancer (clinicaltrials.gov) - Mar 22, 2022
P4, N=70, Not yet recruiting, Sponsor: Chinese Academy of Medical Sciences
- |||| Cipterbin (inetetamab) / 3SBio
New P4 trial, Metastases: Cipterbin Combined With Vinorelbine in the Treatment of HER2-positive MBC (clinicaltrials.gov) - Nov 22, 2021
P4, N=60, Recruiting, Sponsor: Zhejiang Cancer Hospital
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma
New trial: A Study of Diarrhea and Intestinal Flora Changes Caused by Pyrotinib in Breast Cancer (clinicaltrials.gov) - Sep 1, 2021
P, N=50, Recruiting, Sponsor: Zhejiang Cancer Hospital
- | Cipterbin (inetetamab) / 3SBio, utidelone IV (UTD1) / Beijing Biostar Technologies
Enrollment open, Metastases: Exploratory Study of Advanced Breast Cancer in HER2 Positive Patients With Failure of Multi-line Therapy Treated by Combination of Inetetamab (Cipterbin) + PD-1 Inhibitor Combined With Utidelone. (clinicaltrials.gov) - Aug 25, 2021
P2, N=46, Recruiting, Sponsor: Henan Cancer Hospital
Inetetamab plus camrelizumab and utidelone showed promising efficacy and acceptable safety profile in patients with HER2-positive advanced breast cancer after progression on at least two lines of HER2-directed therapies with trastuzumab and TKIs. Not yet recruiting --> Recruiting
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma, Cipterbin (inetetamab) / 3SBio
New P1/2 trial, Combination therapy, Metastases: Inetetamab in Combination With Pyrotinib in HER2 Mutant or Amplified Advanced Non-small Cell Lung Cancer (clinicaltrials.gov) - Aug 22, 2021
P1/2, N=48, Recruiting, Sponsor: Sun Yat-sen University
- | Cipterbin (inetetamab) / 3SBio
New trial, Real-world evidence, Real-world, Metastases: RWS of Inetetamab HER2 Positive Advanced Breast Cancer (clinicaltrials.gov) - Jul 14, 2021
P, N=100, Not yet recruiting, Sponsor: Zhiyong Yu
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma, Cipterbin (inetetamab) / 3SBio, Herceptin (trastuzumab) / Roche
New P2 trial, Metastases: Pyrotinib and Vinorelbine Tartrate Capsules With or Without Inetetamab for First Line Treatment in Patients With Trastuzumab-resistant HER2-positive Advanced Breast Cancer (clinicaltrials.gov) - Jul 14, 2021
P2, N=100, Not yet recruiting, Sponsor: Zhiyong Yu
- | Cipterbin (inetetamab) / 3SBio
New P2 trial, Metastases: Increase: Inetetamab Plus Cyclophosphamide Metronomic Chemotherapy Plus Aromatase Inhibitor in Metastatic HER2+/HR+ Breast Cancer (clinicaltrials.gov) - Jun 28, 2021
P2, N=78, Recruiting, Sponsor: Sun Yat-sen University
- | Cipterbin (inetetamab) / 3SBio, utidelone IV (UTD1) / Beijing Biostar Technologies
Enrollment change, Trial initiation date, Trial primary completion date, Metastases: Exploratory Study of Advanced Breast Cancer in HER2 Positive Patients With Failure of Multi-line Therapy Treated by Combination of Inetetamab (Cipterbin) + PD-1 Inhibitor Combined With Utidelone. (clinicaltrials.gov) - Apr 22, 2021
P2, N=46, Not yet recruiting, Sponsor: Henan Cancer Hospital
Not yet recruiting --> Recruiting N=71 --> 46 | Initiation date: Dec 2020 --> Apr 2021 | Trial primary completion date: Dec 2021 --> Apr 2022
- | Cipterbin (inetetamab) / 3SBio, Herceptin (trastuzumab) / Roche
New P3 trial, Metastases: Inetetamab Plus Rapamycin and Chemotherapy for HER2+ Metastatic Breast Cancer With Abnormal Activation of PAM Pathway (clinicaltrials.gov) - Feb 3, 2021
P3, N=270, Not yet recruiting, Sponsor: Peking Union Medical College
- | Cipterbin (inetetamab) / 3SBio, utidelone IV (UTD1) / Beijing Biostar Technologies
New P2 trial, Metastases: Exploratory Study of Advanced Breast Cancer in HER2 Positive Patients With Failure of Multi-line Therapy Treated by Combination of Inetetamab (Cipterbin) + PD-1 Inhibitor Combined With Utidelone. (clinicaltrials.gov) - Dec 22, 2020
P2, N=71, Not yet recruiting, Sponsor: Henan Cancer Hospital
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma, Cipterbin (inetetamab) / 3SBio
New P2 trial, Metastases: Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer (clinicaltrials.gov) - Dec 22, 2020
P2, N=71, Recruiting, Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- || Cipterbin (inetetamab) / 3SBio, vinorelbine tartrate / Generic mfg.
Clinical, Journal: Phase Ⅲ randomized controlled, multicenter, prospective study of recombinant anti-HER2 humanized monoclonal antibody (Cipterbin) combined with vinorelbine in patients with HER2 positive metastatic breast cancer: the HOPES Study (Pubmed Central) - Aug 29, 2020
The recombinant anti-HER2 humanized monoclonal antibody (Cipterbin) combined with vinorelbine has significant efficacy and good safety. It is the optimized therapy regime for patients with taxane-pretreated HER2 positive metastatic breast cancer, which provides more targeted therapy opportunities for HER2 positive breast cancer patients in China.
- ||||| Cipterbin (inetetamab) / 3SBio
New P2 trial, Combination therapy, Metastases: Study of Cipterbin (clinicaltrials.gov) - Sep 20, 2011
P2, N=109, Completed, Sponsor: Shanghai CP Guojian Pharmaceutical Co.,Ltd.